This follows almost three years of providing chemotherapy compounding services to these hospitals.
The agreement, which was awarded following a public tender process, will see Slade service up to 26 public hospitals across the state across Adelaide, Ceduna, Port Augusta and other regional areas.
CEO David Slade said that Slade welcomed the opportunity to extend its current compounding service in South Australia.
“This is an acknowledgement of the exceptional service that Slade Health has been providing to hospitals in South Australia.”